Skip to Main Content

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Conditions

Phase I

Phase I-II

What is the purpose of this trial?

This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.

  • Trial with
    Astex Pharmaceuticals, Inc.
  • Start Date
    05/13/2018
  • End Date
    07/31/2021
Trial Image

For more information about this study, contact:

Nicole Sinclair

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2020
  • Study HIC
    #2000022408